HANGZHOU BINJIANG
GenericsHANGZHOU BINJIANG is a generic drug manufacturer focused on Cardiovascular.
HANGZHOU BINJIANG's Key Drugs
HANGZHOU BINJIANG's core commercial portfolio centers on OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, spanning Cardiovascular — its most strategically important drugs approved in the last 15 years.
HANGZHOU BINJIANG's Recent FDA Approvals
New NDA/BLA approvals for HANGZHOU BINJIANG over the last two years — novel drugs only, excluding generics and label supplements.
HANGZHOU BINJIANG's Therapeutic Areas
HANGZHOU BINJIANG's approved drugs and pipeline span 1 therapeutic area, led by Cardiovascular, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
HANGZHOU BINJIANG's Top Competitors
HANGZHOU BINJIANG's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
HANGZHOU BINJIANG Pipeline Snapshot
Active clinical trials for HANGZHOU BINJIANG across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2009-09-24
- Latest
- 2025-08-20
- Applications
- 4